Are you including Bortezomib as standard of care in the upfront treatment of T lymphoblastic-lymphoma?

We do use bortezomib in the upfront treatment of T-cell lymphoblastic lymphoma in children and AYA. For those familiar with the topic, the results of two successive large clinical trials in T-LLy done by COG, AALL0434, and AALL1231, were confusing. Due to the rarity of the disease, overlapping trials were planned so that AALL1231 was started before all results of AALL0434 were known. However, after much deliberation, it was concluded that T-LLy patients benefit from the addition of bortezomib in induction and delayed intensification (as per AALL1231 experimental arm), but do not benefit from the use of dexamethasone in induction as was used in AALL1231. Instead, it should be treated with prednisone in induction. The result is that we cannot...